Xeris Historical Income Statement

XERS Stock

USD 3.54 0.07 1.94%

Historical analysis of Xeris Pharmaceuticals income statement accounts such as Interest Income of 5.7 M, Depreciation And Amortization of 15.9 M, Interest Expense of 32.1 M or Selling General Administrative of 176.4 M can show how well Xeris Pharmaceuticals performed in making a profits. Evaluating Xeris Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Xeris Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Xeris Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Xeris Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xeris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Xeris Stock please use our How to Invest in Xeris Pharmaceuticals guide.

About Xeris Income Statement Analysis

Xeris Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Xeris Pharmaceuticals shareholders. The income statement also shows Xeris investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Xeris Pharmaceuticals Income Statement Chart

At this time, Xeris Pharmaceuticals' Reconciled Depreciation is comparatively stable compared to the past year.

Interest Income Other Operating Expenses Net Income From Continuing Ops Ebit

Interest Income

Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Xeris Pharmaceuticals. It is also known as Xeris Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Xeris Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Xeris Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xeris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Xeris Stock please use our How to Invest in Xeris Pharmaceuticals guide.At this time, Xeris Pharmaceuticals' Reconciled Depreciation is comparatively stable compared to the past year.

	2022	2023	2024	2025 (projected)
Depreciation And Amortization	12.7M	13.2M	15.1M	15.9M
Interest Income	2.6M	4.8M	5.5M	5.7M

Depreciation And Amortization Interest Income

Xeris Pharmaceuticals income statement Correlations

	Net Interest Income	Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Reconciled Depreciation	Tax Provision	Non Operating Income Net Other
Net Interest Income		-0.93	-0.96	-0.98	-0.95	-0.95	-0.95	-0.88	0.35	0.47	0.26	-0.19	0.13	-0.95	-0.87	0.51	0.99	0.5	0.71	-0.95	0.81	0.85
Interest Income	-0.93		0.91	0.92	0.87	0.83	0.83	0.78	-0.44	-0.49	-0.3	0.4	-0.18	0.83	0.78	-0.57	-0.9	-0.56	-0.49	0.88	-0.7	-0.71
Depreciation And Amortization	-0.96	0.91		0.94	0.92	0.94	0.94	0.81	-0.28	-0.38	-0.17	0.15	-0.03	0.93	0.8	-0.44	-0.96	-0.43	-0.69	1.0	-0.91	-0.77
Interest Expense	-0.98	0.92	0.94		0.97	0.98	0.97	0.87	-0.37	-0.51	-0.3	0.21	-0.18	0.98	0.87	-0.53	-0.97	-0.52	-0.7	0.93	-0.75	-0.84
Selling General Administrative	-0.95	0.87	0.92	0.97		0.95	0.95	0.93	-0.51	-0.65	-0.46	0.27	-0.34	0.98	0.93	-0.66	-0.96	-0.65	-0.76	0.9	-0.75	-0.9
Total Revenue	-0.95	0.83	0.94	0.98	0.95		1.0	0.85	-0.24	-0.41	-0.2	0.07	-0.08	0.99	0.83	-0.41	-0.95	-0.4	-0.74	0.94	-0.82	-0.83
Gross Profit	-0.95	0.83	0.94	0.97	0.95	1.0		0.84	-0.22	-0.39	-0.18	0.06	-0.06	0.99	0.82	-0.39	-0.94	-0.38	-0.74	0.94	-0.82	-0.81
Other Operating Expenses	-0.88	0.78	0.81	0.87	0.93	0.85	0.84		-0.63	-0.75	-0.6	0.39	-0.5	0.88	1.0	-0.75	-0.9	-0.75	-0.72	0.79	-0.67	-0.86
Operating Income	0.35	-0.44	-0.28	-0.37	-0.51	-0.24	-0.22	-0.63		0.97	0.97	-0.82	0.95	-0.32	-0.67	0.98	0.38	0.98	0.29	-0.21	0.11	0.49
Net Income From Continuing Ops	0.47	-0.49	-0.38	-0.51	-0.65	-0.41	-0.39	-0.75	0.97		0.97	-0.72	0.93	-0.49	-0.78	0.99	0.51	0.99	0.45	-0.32	0.2	0.64
Ebit	0.26	-0.3	-0.17	-0.3	-0.46	-0.2	-0.18	-0.6	0.97	0.97		-0.74	0.99	-0.29	-0.64	0.95	0.3	0.95	0.31	-0.11	0.01	0.48
Research Development	-0.19	0.4	0.15	0.21	0.27	0.07	0.06	0.39	-0.82	-0.72	-0.74		-0.73	0.09	0.43	-0.77	-0.17	-0.77	0.07	0.09	-0.05	-0.07
Ebitda	0.13	-0.18	-0.03	-0.18	-0.34	-0.08	-0.06	-0.5	0.95	0.93	0.99	-0.73		-0.17	-0.53	0.9	0.17	0.91	0.22	0.03	-0.12	0.38
Cost Of Revenue	-0.95	0.83	0.93	0.98	0.98	0.99	0.99	0.88	-0.32	-0.49	-0.29	0.09	-0.17		0.87	-0.49	-0.96	-0.48	-0.77	0.93	-0.79	-0.89
Total Operating Expenses	-0.87	0.78	0.8	0.87	0.93	0.83	0.82	1.0	-0.67	-0.78	-0.64	0.43	-0.53	0.87		-0.78	-0.89	-0.78	-0.71	0.77	-0.66	-0.85
Income Before Tax	0.51	-0.57	-0.44	-0.53	-0.66	-0.41	-0.39	-0.75	0.98	0.99	0.95	-0.77	0.9	-0.49	-0.78		0.54	1.0	0.42	-0.37	0.25	0.63
Total Other Income Expense Net	0.99	-0.9	-0.96	-0.97	-0.96	-0.95	-0.94	-0.9	0.38	0.51	0.3	-0.17	0.17	-0.96	-0.89	0.54		0.53	0.75	-0.95	0.82	0.89
Net Income	0.5	-0.56	-0.43	-0.52	-0.65	-0.4	-0.38	-0.75	0.98	0.99	0.95	-0.77	0.91	-0.48	-0.78	1.0	0.53		0.41	-0.36	0.24	0.62
Income Tax Expense	0.71	-0.49	-0.69	-0.7	-0.76	-0.74	-0.74	-0.72	0.29	0.45	0.31	0.07	0.22	-0.77	-0.71	0.42	0.75	0.41		-0.68	0.63	0.73
Reconciled Depreciation	-0.95	0.88	1.0	0.93	0.9	0.94	0.94	0.79	-0.21	-0.32	-0.11	0.09	0.03	0.93	0.77	-0.37	-0.95	-0.36	-0.68		-0.93	-0.75
Tax Provision	0.81	-0.7	-0.91	-0.75	-0.75	-0.82	-0.82	-0.67	0.11	0.2	0.01	-0.05	-0.12	-0.79	-0.66	0.25	0.82	0.24	0.63	-0.93		0.57
Non Operating Income Net Other	0.85	-0.71	-0.77	-0.84	-0.9	-0.83	-0.81	-0.86	0.49	0.64	0.48	-0.07	0.38	-0.89	-0.85	0.63	0.89	0.62	0.73	-0.75	0.57

Click cells to compare fundamentals

Xeris Pharmaceuticals Account Relationship Matchups

Xeris Pharmaceuticals income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Net Interest Income	(7.7M)	(6.9M)	(12.7M)	(21.9M)	(19.7M)	(18.7M)
Interest Income	3.0M	313K	2.6M	4.8M	5.5M	5.7M
Depreciation And Amortization	3.0M	1.9M	12.7M	13.2M	15.1M	15.9M
Interest Expense	7.2M	10.7M	15.3M	26.6M	30.6M	32.1M
Selling General Administrative	73.7M	125.7M	137.7M	146.1M	168.0M	176.4M
Total Revenue	2.7M	20.2M	110.2M	163.9M	188.5M	197.9M
Gross Profit	1.1M	10.8M	87.6M	135.3M	155.6M	163.3M
Other Operating Expenses	125.1M	103.7M	192.2M	207.9M	239.1M	127.2M
Operating Income	(122.4M)	(83.5M)	(81.9M)	(44.0M)	(39.6M)	(41.6M)
Net Income From Continuing Ops	(91.1M)	(122.7M)	(94.7M)	(62.3M)	(56.0M)	(58.8M)
Ebit	(83.5M)	(115.5M)	(82.0M)	(36.9M)	(33.2M)	(34.9M)
Research Development	60.4M	20.9M	21.0M	22.3M	20.1M	21.7M
Ebitda	(80.6M)	(113.7M)	(69.3M)	(23.7M)	(21.4M)	(22.4M)
Cost Of Revenue	1.6M	9.3M	22.6M	28.6M	32.9M	34.6M
Total Operating Expenses	123.5M	94.4M	169.6M	179.3M	206.2M	115.6M
Income Before Tax	(126.0M)	(91.3M)	(96.1M)	(63.5M)	(57.2M)	(60.0M)
Total Other Income Expense Net	(7.7M)	(7.6M)	(14.1M)	(19.5M)	(17.5M)	(16.7M)
Net Income Applicable To Common Shares	(125.6M)	(91.1M)	(122.7M)	(94.7M)	(85.2M)	(89.5M)
Net Income	(125.6M)	(91.1M)	(94.7M)	(62.3M)	(56.0M)	(58.8M)
Income Tax Expense	(458K)	(110K)	(1.4M)	(1.2M)	(1.1M)	(1.1M)
Reconciled Depreciation	1.5M	1.9M	12.7M	13.2M	15.1M	15.9M
Tax Provision	(110K)	(408K)	(1.4M)	(1.2M)	(1.1M)	(1.2M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Xeris Stock Analysis

When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Xeris Historical Income Statement

About Xeris Income Statement Analysis

Xeris Pharmaceuticals Income Statement Chart

Interest Income

Other Operating Expenses

Xeris Pharmaceuticals income statement Correlations

Xeris Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Xeris Pharmaceuticals income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Xeris Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Reconciled Depreciation	+ 1.0	Depreciation And Amortization
Gross Profit	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Other Operating Expenses
Net Income	+ 1.0	Income Before Tax
Total Other Income Expense Net	+ 0.99	Net Interest Income
Cost Of Revenue	+ 0.99	Total Revenue

Interest Expense	- 0.98	Net Interest Income
Total Other Income Expense Net	- 0.97	Interest Expense
Total Other Income Expense Net	- 0.96	Cost Of Revenue
Total Other Income Expense Net	- 0.96	Selling General Administrative
Total Other Income Expense Net	- 0.96	Depreciation And Amortization
Depreciation And Amortization	- 0.96	Net Interest Income